Experimental hepatitis b drug combo shows promise but study halted early

NCT ID NCT02738008

Terminated Disease control Sponsor: Arrowhead Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested an experimental drug called ARC-520 given alongside standard hepatitis B medications (entecavir or tenofovir) in 12 people with chronic hepatitis B. Participants received 9 doses of ARC-520 over 36 weeks to see if it could safely lower hepatitis B virus levels. The study was terminated early, so results are limited, but it aimed to find a better way to control the virus long-term.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATITIS B are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic hepatitis B virus infection hepatitis B virus infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEPATITIS B

Contacts and locations

Show contact details

Locations

Research Site 1

Hong Kong, 999077, China
Research Site 2

Leipzig, 04103, Germany
Research Site 3

Busan, 602-739, South Korea
Research Site 4

Seoul, 110-744, South Korea
Research Site 5

Incheon, 405-760, South Korea
Research Site 6

Seoul, 120-752, South Korea